ArticleFrontiers in nutrition2025
Prognostic value of the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) in patients with RAS-mutant metastatic colorectal cancer.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Visceral fat area and blood lipids in colorectal cancer: predictors of surgical risk and prognosis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with metastatic colorectal cancer (mCRC) generally have a poor prognosis, and treatment strategies are highly dependent on the RAS mutational status. During disease progression, patients often exhibit dynamic changes in serum lipid profiles. However, the prognostic significance of cholesterol-related biomarkers remains controversial. This study aimed to investigate the association between the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and clinical outcomes in patients with RAS-mutant mCRC. Methods: This retrospective study included 287 RAS-mutant mCRC patients, all of whom received at least three cycles of chemotherapy combined with bevacizumab. Among them, 169 patients were assigned to the training cohort and 118 patients to the validation cohort. Pearson's correlation coefficient and Spearman's rank correlation test were used to assess the relationships between continuous variables. The optimal cutoff value for the NHHR was determined using the maximum selection rank statistic, categorizing patients into high and low NHHR groups. Kaplan-Meier survival curves were used to assess survival in the high and low NHHR groups, with differences between groups compared using the log-rank test. Restricted cubic splines (RCS) were employed to analyze the non-linear relationship between NHHR and mortality risk. Univariate and multivariate Cox regression models were used to assess the independence of NHHR in predicting survival outcomes, with stepwise adjustment for confounders and stratified analysis. A nomogram was constructed based on the final model. Results: After adjusting for confounders, the high NHHR group (>3.45) had a significantly higher mortality risk than the low NHHR group (HR = 2.23, 95% CI: 1.46-3.40, Conclusion: NHHR may serve as a potential prognostic biomarker in patients with RAS-mutant metastatic colorectal cancer. Its putative role in promoting tumor progression through modulation of chronic inflammation warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.